Brief: Lantern Pharma Receives Pre-IND Feedback From FDA, Clearing Path For Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
17/01/2023 15:14
Jan 17 (Reuters) - Lantern Pharma Inc. LTRN.O :
* LANTERN PHARMA RECEIVES PRE-IND FEEDBACK FROM THE FDA,
CLEARING
A PATH FOR DRUG CANDIDATE LP-184’S PHASE 1 CLINICAL TRIAL IN Q2
2023
Source text for Eikon: ID:nBwgqLRNa
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments